Novavax Says European Commission Granted Marketing Authorization For Updated 2024-2025 Nuvaxovid COVID-19 Vaccine
Portfolio Pulse from Benzinga Newsdesk
Novavax announced that the European Commission has granted marketing authorization for its updated 2024-2025 Nuvaxovid COVID-19 vaccine. This follows a positive opinion from the EMA's Committee for Medicinal Products for Human Use.
October 09, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novavax received marketing authorization from the European Commission for its updated Nuvaxovid COVID-19 vaccine for 2024-2025, following a positive EMA opinion.
The marketing authorization from the European Commission is a significant regulatory milestone for Novavax, likely boosting investor confidence and potentially increasing demand for its vaccine in Europe. This positive development is expected to have a favorable impact on NVAX's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100